Skip to main content
| News

Novartis subsidiary Alcon is now an independent company

09.04.2019

Novartis completed the spin-off of the Alcon eye care devices business through a dividend-in-kind distribution. The Basel pharma giant reports it is now positioned for sustained growth and announced the launch of potential blockbusters.

Basel bridge Novartis Campus Rhine River Innovation Business

The successful execution of the spin-off of Alcon allows Novartis to now fully focus on its medicines, the Basel pharma company reported in a press release. This will also lead to higher group margins. In particular, it plans to improve the Innovative Medicines divisions, in which Novartis is aiming for core margins into the mid-30s by 2022. After granting shareholders a dividend of 2.85 Swiss francs per share for 2019, it plans to pay a “strong and growing annual dividend” in future. The share buyback of up to US$ 5 billion announced in June 2018 is expected to be completed this year.

For achieving sustained growth going forward, Novartis is looking to launch ten potential blockbusters in the next two years.  A blockbuster is a drug with annual sales of at least US$ 1 billion. The company also has an additional 20 potential blockbusters on the horizon.

Shares in the spin-off eye specialist Alcon are now listed on the SIX Swiss Exchange and on the New York Stock Exchange. The company was valued at around US$ 27 billion on flotation. “This is an incredibly exciting day for both Novartis and Alcon,” said CEO Vas Narasimhan in the Novartis press release. Alcon has achieved continuous growth and gone public from a position of great strength. “At Novartis, we continue to reimagine ourselves as a leading medicines company powered by breakthrough medicines, data science and advanced therapy platforms.”

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

South Korean pharma firms show interest in the Basel Area

Several South Korean firms from the life sciences industry, including three pharmaceutical multinationals, have visited the Basel Area on fact-finding...

Read More
Gamma Technologies acquires ProFEMAG portfolio
Advanced Manufacturing/AI, Basel Area Business & Innovation, ICT, Innovation, Invest

Gamma Technologies acquires ProFEMAG portfolio

The Basel-based firm ProFEMAG AG has sold its FEMAG software for electrical machine applications to Gamma Technologies. The company based...

Read More
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Databaum establishes headquarters in Basel

Databaum is establishing its headquarters in Basel and plans to grow from its location there. The startup provides the agricultural...

Read More
Clinerion launches patient information platform
Basel Area Business & Innovation, Digital Health, ICT, Innovation, Invest, Life Sciences / biotech

Clinerion launches patient information platform

Basel-based Clinerion is introducing its machine learning platform. It comprises a global network of hospitals and enables researchers to recognize...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

New innovation campus opens in the Basel Area

The Main Campus of the Switzerland Innovation Park Basel Area was officially opened on October 29. In his speech, Federal...

Read More
Sumitovant acquires all shares in Myovant
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sumitovant acquires all shares in Myovant

Sumitovant is in the process of making Basel-based Myovant Sciences a wholly owned subsidiary by acquiring a 100 percent shareholding...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

VectivBio raises 125 million US dollars in stock sale

VectivBio has announced the closing of the subscription offer for 16,700,000 ordinary shares. The Basel-based biotechnology firm has generated gross...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

KetoSwiss secures capital increase of 4 million dollars

KetoSwiss has banked a total of 4 million US dollars from investors. The Basel-based startup develops products to alleviate neurological...

Read More
Basel Area Business & Innovation, Invest, Life Sciences / biotech

Escientia Switzerland becomes Primopus

The Indian company Deccan Fine Chemicals is acquiring Escientia Switzerland and renaming it as Primopus AG. The new owner announces...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Novartis investing 100 million Swiss francs in new biologics center

The pharmaceutical company Novartis is investing a sum of 100 million Swiss francs in a new competence center for biologics...

Read More
1 2 3 35

Do you have a question? We'd like to hear from you.